Cargando…
Developing therapeutic monoclonal antibodies at pandemic pace
The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173776/ https://www.ncbi.nlm.nih.gov/pubmed/32317764 http://dx.doi.org/10.1038/s41587-020-0512-5 |